Contents 1 min reading

Claim and source comparison

Vinpocetine: dementia research and the FDA pregnancy safety warning.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Systematic review / meta-analysis

The 2003 Cochrane review analysed available data for 583 people with dementia across 3 studies. Some measures differed, but the authors found the evidence insufficient to support clinical use.

Diagnostic criteria varied, adverse effects were reported inconsistently and intention-to-treat data were unavailable. These results cannot be generalized to healthy people.

Source 7 · Abstract read

Official safety summary

In 2019 the FDA advised pregnant people and those who could become pregnant to avoid vinpocetine because of possible miscarriage or harm to fetal development.

This is a reproductive safety warning. The tentative US assessment of supplement status announced in 2016 is a separate matter.

Source 6 · Official summary read

Our evidence and source methodology

vinpocetine: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Vinpocetine?

Vinpocetine is a synthetic ethyl ester of apovincamine.

Mechanism of Effect

vinpocetine: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans. This schematic mechanism illustration does not establish clinical benefit in humans, a receptor reset or a safe dosing schedule.

Clinical Evidence

Hindmarch et al. (1991) studied 203 patients with organic psychosyndromes, not healthy older adults, for 16 weeks with placebo or vinpocetine 3×10/3×20 mg daily. Subhan and Hindmarch (1985) yielded short-term, limited test findings in 12 healthy women, not evidence of general cognitive enhancement.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Sources

  1. Hindmarch I, et al. (1991). Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. International Clinical Psychopharmacology, 6(1), 31–43. PubMed · PMID 2071888
  2. Subhan Z & Hindmarch I (1985). Psychopharmacological effects of vinpocetine in normal healthy volunteers. European Journal of Clinical Pharmacology, 28(5), 567–571. PubMed · PMID 3899677
  3. Bereczki D & Fekete I (2008). Vinpocetine for acute ischaemic stroke. Cochrane Database of Systematic Reviews, (1), CD000480. PubMed · PMID 18253980
  4. Valikovics A (2007). Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz, 60(7–8), 301–310. PubMed · PMID 17713111
  5. Kemény V, et al. (2005). Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. Journal of Clinical Pharmacology, 45(9), 1048–54. https://doi.org/10.1177/0091270005279363 PubMed · PMID 16100299
  6. US Food and Drug Administration. Vinpocetine in Dietary Supplements. https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/vinpocetine-dietary-supplements US Food and Drug Administration
  7. Szatmari SZ, Whitehouse PJ. (2003). Vinpocetine for cognitive impairment and dementia. Cochrane Database of Systematic Reviews, (1), CD003119. PubMed · PMID 12535455

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions